Sometimes it is helpful to refresh our minds with a review of the past. Following is a distillation of press releases since the founding of ZE 10 years ago.

 

I find the start up investing phase with Eastern, NGN BioMed and then the entry of Newsoara very exciting.

 

Even more exciting are the connections, # of trials and indications, drug combinations, connections including the NCI and BP collaborators in what I believe now is 11 clinical trials.

 

What is extremely disappointing is the lack of creation of shareholder value given such exciting science.

 

Also, what seems a bit disturbing is the June 16th waiver of future milestones (due from Newsoara) and what I believe to be th granting of zen3694 patents to Newsoara in "The Territories". I really don't understand this.

 

Eventhing is date referenced so if you want to see details go to the ZCC website and check the actual full post and related links.

 

It's fun reading.

GLTA

Toinv

 

ZCC History Aug 22 2023 Master 1

 

Zenith Epigenetics Corp. Commences Operations

June 13, 2013 - CALGARY, June 3, 2013 /CNW/ - Zenith Epigenetics Corp. ("Zenith") commenced operations today as an early stage research company. Zenith was formed as a result of a plan of arrangement (the "Arrangement") involving Resverlogix Corp. ("Resverlogix"), RVX Therapeutics Inc. ("Therapeutics") and Zenith pursuant to which Resverlogix spun-out Therapeutics to Zenith.

 

Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.

 

Management and Directors

The management team of Zenith will be led by the management team of Resverlogix, including Donald McCaffrey as President and Chief Executive Officer, Brad Cann as Chief Financial Officer, Kenneth Lebioda as Senior VP Business & Corporate Development, Dr. Norman Wong, as Chief Scientific Officer and Chairman of the Scientific Advisory Board, Dr. Jan Johansson, as Senior VP Medical Affairs, Dr. Gregory Wagner, as Senior VP Research and Development and Dr. Allan Gordon, as Senior VP Clinical Development.

 

The board of directors of Zenith consists of Dr. Peter Johann, Donald McCaffrey, Kenneth Zuerblis, Dr. Eldon Smith, Kelly McNeill and Arthur J. Higgins.

 

Zenith Epigenetics Board Update & Webcast Announcement

CALGARY, Feb. 11, 2014 /CNW/ - Zenith Epigenetics announced today that Arthur Higgins will be stepping down from the Board of Directors …

In addition, Zenith Epigenetics Corp. will be hosting a conference call and webcast on Thursday, February 20, 2014 at 11 am MDT / 1 pm ET. The call will update the market on current developments and clinical progress.

 

Zenith Epigenetics Closes $8 million Private Placement

CALGARY, March 14, 2014 /CNW/ - Zenith Epigenetics Corp.  today announced that it has closed a private placement of 8,000,000 common shares at a price of US$1.00 per share for gross proceeds of US$8,000,000 (the "Private Placement") to Eastern Capital Limited ("Eastern") and NGN BioMed Opportunity II, L.P. ("NGN"). Eastern and NGN subscribed for 6,000,000 and 2,000,000 common shares, respectively. The shares are subject to a four month hold period.

 

Zenith Epigenetics Appoints Julie Cherrington as President and CEO

CALGARY, July 23, 2014 /CNW/ - Zenith Epigenetics Corp.  today announced that it has appointed Julie Cherrington PhD to act as the President and Chief Executive Officer of Zenith Epigenetics Corp. Julie has an extensive background leading companies focused on the discovery and development of novel cancer therapeutics and is well-versed in the challenges of developing drugs and advancing them into the clinic and through to commercialization. 

 

Notably, Julie was a key contributor to the successful development of multiple FDA approved products including anti-virals (Vistide™, Viread™, Hepsera™) and anti-cancer agents (SUTENT™, Palladia™).

 

Zenith Epigenetics Closes $4.6 million Private Placement

CALGARY, July 23, 2014 /CNW/ - Zenith Epigenetics Corp.  today announced that it has closed a private placement of 4.3 million common shares at a price of US$1.00 per share for gross proceeds of CAD$4.6 million (the "Private Placement"). NGN BioMed Opportunity II, L.P. ("NGN") subscribed for 1,000,000 common shares.

 

Zenith Epigenetics Strengthens its Management Team with Key Appointments

CALGARY, Sept. 8, 2014 /CNW/ - Zenith Epigenetics Corp.  today announced that it has appointed 

·       Joy Zhu, MD, PhD, as Chief Medical Officer, 

·       Sanjay Lakhotia, PhD, as Chief Business Officer, and 

·       Michael Yakes, PhD, as Vice President Drug Discovery and Exploratory Development.

 

Zenith Epigenetics Update

CALGARY, Oct. 14, 2014 /CNW/ - Zenith Epigenetics Corp.  today announced that due to recent business developments it is suspending its clinical development efforts with ZEN-3365, one of its proprietary BET inhibitors.

 

Zenith Epigenetics Announces Change in Executive Leadership

CALGARY, April 30, 2015 /CNW/ - Zenith Epigenetics Corp.  today announced that Julie Cherrington will be leaving the Company, effective April 29, 2015. Donald McCaffrey, Chairman of Zenith's Board of Directors, will assume the role as Interim President and Chief Executive Officer until a permanent replacement is appointed.

 

Zenith Epigenetics Closes $4 million Private Placement

CALGARY, May 19, 2015 /CNW/ - Zenith Epigenetics Corp.  today announced that it has closed a private placement of 4,000,000 common shares at a price of US$1.00 per share for gross proceeds of US$4,000,000 (the "Private Placement") to Eastern Capital Limited.

 

Zenith Epigenetics Appoints Dr. Norman C.W. Wong to the Board of Directors

CALGARY, Nov. 30, 2015 /CNW/ - Zenith Epigenetics Corp.  today announced that it has appointed Dr. Norman C.W. Wong to its Board of Directors to replace Dr. Peter Johann.

 

Zenith Epigenetics Closes $24.6 Million USD Private Placement

CALGARY, May 16, 2016 /CNW/ - Zenith Epigenetics Corp.  today announced that it has closed a private placement of 24,560,500 common shares at a price of US$1.00 per share for gross proceeds of US$24,560,500 (the "Private Placement") to Eastern Capital Limited.

 

Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details

June 15, 2016

 

Corporate Update Webcast

Zenith announces it will be hosting a corporate update via webcast on Monday, June 20, 2016 at 11:00 am MT / 1:00 pm ET.

 

Zenith Epigenetics Corp. Announces Name Change and Internal Corporate Reorganization

CALGARY, Aug. 2, 2016 /CNW/ - Zenith Epigenetics Corp. announced today that it has changed its name to Zenith Capital Corp…

 

Zenith Capital Corp. Announces Annual and Special Meeting Webcast Details

December 7, 2016

 

December 14, 2016 - Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694

CALGARY, Dec. 14, 2016 /CNW/ - Zenith Capital Corp. today announced that its wholly owned subsidiary, Zenith Epigenetics Ltd., has initiated a Phase 1b clinical trial in metastatic Castration Resistant Prostate Cancer ("mCRPC") patients, dosing ZEN-3694 in combination with enzalutamide. 

 

Zenith Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

CALGARY, Jan. 5, 2017 /CNW/ - Zenith Capital Corp.  today announces its participation in the upcoming 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. 

 

Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

CALGARY, June 5, 2017 /CNW/ - Zenith Capital Corp. announced that a patent covering its clinical compound, ZEN-3694, has been issued by the United States Patent and Trademark Office (USPTO).

 

2017 BIO International Convention Presentation Details

Date: Tuesday, June 20th

Zenith Announces Annual General Meeting of Shareholders

October 2, 2017

 

Zenith Announces Webcast Presentation at the BIO Investor Forum in San Francisco, CA

October 16, 2017

 

Zenith Announces Further Advancement of Clinical Trial with ZEN-3694, a Proposed Equity Offering and an Update Webcast

CALGARY, Alberta, June 04, 2018 (GLOBE NEWSWIRE) -- Zenith Capital Corp. today announced that its wholly owned subsidiary, Zenith Epigenetics Ltd. , has initiated the Phase 2 portion of the ongoing metastatic Castration Resistant Prostate Cancer ("mCRPC") clinical trial in patients that have progressed on an androgen receptor antagonist (ARi). 

 

Private Placement

The Company also announced that it intends to complete an equity private placement of up to 10 million common shares (the “Offering”).

 

Webcast Presentation at the 2018 BIO International Convention  

Date: Monday, June 4, 2018 

Zenith Capital Closes $5.7 Million Private Placement

CALGARY, Alberta, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Zenith Capital Corp.  today announced that it has closed a private placement of approximately 2.2 million units at a price of US$2.00 per unit for gross proceeds of approximately $5.7 million (US$4.4 million) (the "Private Placement") with Eastern Capital Limited and other subscribers. Each unit is comprised of one (1) common share and one-half (1/2) of a common share purchase warrant exercisable at US$3.00 per share for a period of three (3) years. 

 

Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study

CALGARY, Alberta, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., announced today the publication of a scientific article on the effect of ZEN-3694, Zenith’s novel small molecule BET (bromodomain and extra-terminal) inhibitor, in a patient with metastatic castrate resistant prostate cancer (“mCRPC”).

 

Advanced Therapeutics (Wiley) published: “Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform”. 

The full report can be accessed here:

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adtp.201800104

 

Zenith Announces Voting Results from the 2018 Annual Meeting of Shareholders

September 12, 2018

 

Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains

CALGARY, Alberta, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd.  , a wholly-owned subsidiary of Zenith Capital Corp., announced today the publication of a scientific article in the prestigious Journal of Medicinal Chemistry entitled: “Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine”.

 

Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer

Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019

CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. , a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has entered into a clinical trial collaboration with Pfizer Inc. (“Pfizer”; NYSE: PFE) to evaluate the safety and efficacy of a novel anti-cancer combination of Zenith’s investigational bromodomain and extra-terminal domain inhibitor (“BETi”), ZEN-3694, and Pfizer’s poly ADP ribose polymerase inhibitor (“PARPi”), talazoparib, in patients with locally advanced or metastatic triple negative breast cancer (“TNBC”).

 

Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program

Pfizer / Zenith TNBC program collaboration on target to dose first patient in April 2019

Phase 2 mCRPC program and clinical data to be presented at AACR

CALGARY, Alberta, March 18, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. , a wholly-owned subsidiary of Zenith Capital Corp., announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s investigational new drug application for ZEN-3694, a novel and differentiated  bromodomain and extra-terminal domain inhibitor (“BETi”), for triple negative breast cancer (“TNBC”) in combination with talazoparib, a poly ADP ribose polymerase inhibitor (“PARPi”).

 

As announced on November 20, 2018, Pfizer Inc. (“Pfizer”; NYSE: PFE) and Zenith are collaborating on a Phase 1b/2 clinical trial of ZEN-3694 and Pfizer’s PARPi, talazoparib, in patients with locally advanced or metastatic TNBC without germline BRCA1/2 mutations. First dosing is expected in April 2019.

 

·       April 1, 2019

o   A phase 1b/2a study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer

o   The poster will be available on the Company’s website HERE at the appropriate time.

 

Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. , a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the first patient in a Phase 1b/2 clinical trial undertaken in collaboration with Pfizer Inc. (“Pfizer”). The trial will evaluate the combination, safety and efficacy of the Company’s ZEN-3694, a novel and differentiated bromodomain and extra-terminal domain inhibitor (“BETi”), and Pfizer’s talazoparib, a poly ADP ribose polymerase inhibitor (“PARPi”), in patients with locally advanced or metastatic triple negative breast cancer without germline BRCA1/2 mutations.

 

Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

CALGARY, Alberta, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics” or the “Company”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara BioPharma Co., Ltd. (“Newsoara”) for the Company’s lead compound, ZEN-3694, in China, Hong Kong, Taiwan, and Macau (the “Territories”).

 

Under the terms of the agreement, Newsoara will have the rights to develop, market, and distribute ZEN-3694 for all indications in the Territories. Newsoara will pay Zenith Epigenetics upfront and near-term development milestone payments totaling US$15 million.

 

In addition, today Zenith announced that it has closed a private placement of approximately 1.1 million units at a price of US$2.00 per unit for gross proceeds of approximately US$2.1 million.

 

Zenith Announces Annual and Special Meeting of Shareholders

August 22, 2019

 

Zenith Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders

October 31, 2019

 

Zenith Epigenetics Announces Clinical Advancement of ZEN-3694

CALGARY, Alberta, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd.  announced today the significant clinical advances of ZEN-3694, the Company’s lead compound being developed for epigenetic combination therapies in oncology.

 

The US FDA has given us positive feedback on potential development paths for our metastatic castration resistant prostate cancer program, including the potential for an accelerated approval. In the meantime, we continue to evaluate a number of scenarios for progressing ZEN-3694 towards registration-enabling studies.”

 

Zenith Epigenetics Receives US$5 Million Milestone Payment from Newsoara

CALGARY, Alberta, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd.  announced receipt of a US$5 million milestone payment, less applicable taxes, from Newsoara BioPharma Co., Ltd. related to a previously announced licensing agreement for the Company’s lead compound, ZEN-3694, in China, Hong Kong, Taiwan, and Macau. ZEN-3694 is being developed for epigenetic combination therapies in oncology for multiple indications.

 

Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment

CALGARY, Alberta, June 16, 2020 (GLOBE NEWSWIRE) -- Zenith Capital Corp.  today announces it will be hosting a corporate update via conference call and webcast on Thursday, June 18, 2020 at 9:00 am MT / 11:00 am ET.

 

Zenith also announces that it has entered into a definitive stock purchase agreement with an affiliate of Newsoara Biopharma Co., Ltd. for the private placement of 3,333,334 common shares in tranches at a price of US$1.50 per share for gross proceeds of US$5 million (CAD$6.7 million) on or before August 31, 2020 (the “Private Placement”).

 

Zenith has completed the issuance of 1,333,334 common shares to the Subscriber for gross proceeds of US$2 million and the subscription for the remaining 2,000,000 common shares for additional gross proceeds of US$3 million is conditional upon customary closing conditions and certain amendments to the previously announced license agreement between Zenith’s subsidiary, Zenith Epigenetics Ltd., and Newsoara Biopharma Co., Ltd., including the waiver of a potential future clinical development milestone payment and the assignment of patents in the territories to Newsoara Biopharma Co., Ltd. that are the subject of the license agreement, with Zenith retaining a right to re-acquire the patents for no additional consideration.

 

Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs

Merck to Collaborate with UCSF and Zenith in a New Phase 2 mCRPC Clinical Trial

CALGARY, Alberta, July 29, 2020 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd.  announced today significant clinical advances of ZEN-3694, the Company’s lead therapeutic compound being developed for epigenetic combination therapies in multiple oncology indications.

 

Metastatic Castration Resistant Prostate Cancer (mCRPC) – Immune-Oncology Combination; UCSF / Zenith / Merck Collaboration

A University of California San Francisco (UCSF) principal investigator led Phase 2 clinical trial in collaboration with Zenith and Merck is being initiated in mCRPC patients who have progressed on an androgen receptor signaling inhibitor (ARSi) and includes patients whose tumors are no longer dependent on androgen

receptor signaling.

 

Triple Negative Breast Cancer (TNBC) – PARPi Combination; Pfizer Collaboration

The TNBC collaboration study, combining ZEN-3694 with Pfizer’s talazoparib, a poly ADP ribose polymerase inhibitor (PARPi), has progressed to Phase 2 of this Phase1b/2 trial. Clinical data to date shows that the combination is active and well tolerated. Ongoing results from this study will be presented at a major scientific conference later this year. Additional information on the study can be accessed HERE.

 

Zenith Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption

August 26, 2020

 

Zenith Provides Update Regarding Extension of its Filing Calendar

September 17, 2020

 

Zenith Provides Update Regarding Extension of its Filing Calendar

October 1, 2020

 

Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

October 5, 2020

First Clinical Study to Combine ZEN-3694 with BMS’s (Bristol, Myers, Squib) Immune Checkpoint Inhibitors nivolumab and ipilimumab for Treatment of Ovarian Cancer

 

Zenith Provides Update Regarding Extension of its Filing Calendar

October 9, 2020

Confirms Annual Filings on SEDAR

 

Zenith Confirms Interim Filings on SEDAR

CALGARY, Alberta, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zenith Capital Corp.  today announces that, further to its October 9, 2020 press release, it today has filed its interim financial statements and related MD&A for the three months ended July 31, 2020. These filings can be found at www.sedar.com under the Company’s profile.

 

Zenith Files Notice of Annual and Special Meeting of Shareholders

Tuesday, December 22, 2020 commencing at approximately 2:00 pm (MT).

 

Zenith Announces Voting Results from the 2020 Annual and Special Meeting of Shareholders

December 22, 2020

 

Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA

March 15, 2021

Novel UCSF investigator led Phase 2 clinical study to address role of epigenetic therapy in mitigating resistance to immune-oncology drugs

 

Zenith Epigenetics Announces Clinical Collaboration with Astellas

April 22, 2021

To Evaluate the Combination of ZEN-3694 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

 

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer

June 24, 2021

Provides Compelling Rationale for the Upcoming Phase 2b Clinical Study in Patients with Poor Response to Androgen Receptor Signaling Inhibitors

 

Zenith Epigenetics Announces a Publication in the Journal of Cancer Gene Therapy with Compelling Data for the Treatment of ER-Positive Breast Cancer Patients

August 17, 2021 - ZEN-3694 has therapeutic potential in combination with CDK4/6 inhibitors in patients with advanced ER+ breast cancer resistant to CDK4/6 inhibitors

 

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study

September 21, 2021 - Evaluating the Combination of ZEN-3694 and Enzalutamide in mCRPC Patients Who Responded Poorly to Prior Abiraterone Treatment

 

Dr. Benny Li, Chief Executive Officer of Newsoara added, “with promising data from the completed Phase 1b/2a trial, the initiation of the multi-national, randomized Phase 2b clinical study in patients with mCRPC is a significant milestone for us to pursue a novel treatment through our partnership with Zenith.”

 

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment

CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp.  announced today that Zenith Epigenetics Ltd. , a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) for Zenith Epigenetics’ lead compound, ZEN-3694, in Asia excluding Middle East and North Africa (“MENA”), India, and ten Eurasian countries (the “Territories”).

 

Under the terms of the agreement, Newsoara will have the rights to develop, market, and distribute ZEN-3694 for all indications in the Territories. Zenith will receive an upfront payment of US$3.5 million, sales-based milestones and single digit royalties.

 

Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update

CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Zenith Capital Corp.  today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors.

 

Dr. Thompson is an experienced biotechnology founder and executive having served as a public company CEO for 22 years. He has served as Chairman, Director, and an Audit Committee member on a number of public company (NASDAQ, TSX and CDNX) boards of directors, and has served as a Director of private company boards and industry groups (including Chairman and Chairman Emeritus of BIOTECanada). He has taken companies public on the TSX, NASDAQ …

 

Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO

February 22, 2022

National Cancer Institute Sponsored Phase 1/1b clinical study to test combination of epigenetic and immune-oncology therapies in solid tumors and ovarian cancer

 

“I am very excited to move this combination concept into the clinic through the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP),” said Dr. Haider Mahdi, a principal investigator and medical oncologist at University of Pittsburgh Medical Center. “We have shown preclinically that BET inhibitors enhance the activity of checkpoint inhibitors by improving the tumor immune microenvironment. We expect the combination to be particularly effective in patients with MYC and BRD4 amplified ovarian cancer which has very poor outcomes and is difficult to treat.”

 

Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

May 10, 2022

Data from the completed Phase 1b/2 trial to be presented at the American Society of Clinical Oncology (ASCO) Conference in an oral poster discussion session.

 

Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)

June 21, 2022

Zenith’s ASCO Poster was Also Awarded the GRASP Advocate Choice Award by a Patient Advocacy Group

 

Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials

July 6, 2022

Seven NCI sponsored trials will evaluate safety and efficacy of its BET inhibitor (BETi) ZEN-3694 in combination with several targeted agents and/or chemotherapy in several solid tumor types with significant unmet need

 

Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

June 1, 2023

Zenith’s BET inhibitor ZEN-3694 providing significant clinical benefit in patients with aggressive cancer type.